Skip to main content
//empty //empty
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 0.1900
Day High 0.2000
Open:0.2000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
- GlobeNewswire - Wed Sep 16, 5:55AM CDT
GlobeNewswire - CMTX
Wed Sep 16, 5:55AM CDT
Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September 14, 2020. Mr. Ford assumes the responsibilities formerly held by Jean-Francois Boily, Vice-President, Finance, who recently resigned.
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
- GlobeNewswire - Fri Sep 11, 6:29AM CDT
GlobeNewswire - CMTX
Fri Sep 11, 6:29AM CDT
Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST) announced that it has filed and mailed the information circular and management proxy statement (the "Circular") for its upcoming annual and special meeting of shareholders to be held on September 30, 2020 (the "Meeting"). The Meeting will take place at 1:00 p.m. Eastern Time, online only, via a virtual meeting portal, through which shareholders of the Company can listen to the Meeting, submit questions and vote online. For more information regarding the Meeting and how to attend and vote at the Meeting, shareholders can consult the Circular, which is available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
- GlobeNewswire - Mon Aug 31, 6:00AM CDT
GlobeNewswire - CMTX
Mon Aug 31, 6:00AM CDT
Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.1830 +6.45% increase
on 09/04/20
Period Open:0.7145
Price movement based on the high, low and last over the given period.
0.8300 -76.53% decrease
on 08/19/20
-0.5197 (-72.74%) decrease
since 08/17/20
3-Month 0.1830 +6.45% increase
on 09/04/20
Period Open:0.7576
Price movement based on the high, low and last over the given period.
0.9400 -79.28% decrease
on 06/18/20
-0.5628 (-74.29%) decrease
since 06/17/20
52-Week 0.1830 +6.45% increase
on 09/04/20
Period Open:2.1700
Price movement based on the high, low and last over the given period.
3.0800 -93.68% decrease
on 12/23/19
-1.9752 (-91.02%) decrease
since 09/17/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies